How have XCUR shares performed in 2023?

Exicure's stock was trading at $1.15 on January 1st, 2023. Since then, XCUR shares have decreased by 59.1% and is now trading at $0.4701. View the best growth stocks for 2023 here .

When is Exicure's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, December 4th 2023. View our XCUR earnings forecast .

How were Exicure's earnings last quarter?

Exicure, Inc. (NASDAQ:XCUR) posted its quarterly earnings results on Friday, November, 19th. The company reported ($8.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.70) by $5.40. The business had revenue of ($3.68) million for the quarter, compared to analyst estimates of $0.80 million.

When did Exicure's stock split?

Exicure's stock reverse split on the morning of Thursday, June 30th 2022. The 1-30 reverse split was announced on Thursday, June 30th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 30th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

How do I buy shares of Exicure?

Shares of XCUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Exicure Stock Price, News & Analysis (NASDAQ:XCUR)

$0.47

+0.01 (+2.17%)

(As of 12/1/2023 ET)

Compare

Today's Range: $0.46
▼
$0.48
50-Day Range: $0.46
▼
$0.78
52-Week Range: $0.44
▼
$1.78

Volume: 5,699 shs
Average Volume: 15,011 shs
Market Capitalization: $4.07 million

P/E Ratio: 0.28
Dividend Yield: N/A
Price Target: N/A

Exicure MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
3.00% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.67
Upright™ Environmental Score
News Sentiment: 0.93
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.14 out of 5 stars

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Exicure.

3.0

Short Interest

Percentage of Shares Shorted
3.00% of the float of Exicure has been sold short.
Short Interest Ratio / Days to Cover
Exicure has a short interest ratio ("days to cover") of 9.
Change versus previous month
Short interest in Exicure has recently decreased by 2.44%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Exicure does not currently pay a dividend.
Dividend Growth
Exicure does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Exicure has received a 74.39% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Preclinical research services for mental health", "Clinical research services for cancer", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Exicure is -0.67.

2.7

News and Social Media Coverage

News Sentiment
Exicure has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Exicure this week, compared to 0 articles on an average week.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Exicure insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.90% of the stock of Exicure is held by insiders.
Percentage Held by Institutions
46.91% of the stock of Exicure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Exicure is 0.28, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 116.64.
Price to Earnings Ratio vs. Sector
The P/E ratio of Exicure is 0.28, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 129.05.
Price to Book Value per Share Ratio
Exicure has a P/B Ratio of 0.16. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Exicure Stock (NASDAQ:XCUR)

Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

XCUR Stock Price History

30 days | 90 days | 365 days | Advanced Chart

XCUR Stock News Headlines

November 28, 2023 | msn.com

Exicure receives Nasdaq delinquency notice on late filing of its form 10-Q

November 9, 2023 | morningstar.com

Exicure Inc XCUR

December 3, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

August 29, 2023 | finance.yahoo.com

Lacklustre Performance Is Driving Exicure, Inc.'s (NASDAQ:XCUR) 25% Price Drop

August 23, 2023 | msn.com

Exicure names new CEO, CFO, directors in wake of resignations

August 15, 2023 | finance.yahoo.com

Exicure First Half 2023 Earnings: US$1.38 loss per share (vs US$3.71 loss in 1H 2022)

August 11, 2023 | marketwatch.com

Exicure: Substantial Financing Needed to Continue Operations

August 11, 2023 | businesswire.com

Exicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update

December 3, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

July 14, 2023 | finance.yahoo.com

Exicure, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 26, 2023 | msn.com

Exicure board backs CEO Kim's strategic alternative view for company

May 26, 2023 | finance.yahoo.com

Exicure, Inc. Announces Support of CEO in its Ongoing Exploration of Strategic Alternatives

May 25, 2023 | sg.finance.yahoo.com

Exicure, Inc. (XCUR) stock price, news, quote & history – Yahoo Finance

May 19, 2023 | seekingalpha.com

Exicure gets Nasdaq non-compliance notice for not filing 10-Q

April 27, 2023 | finance.yahoo.com

Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors

March 28, 2023 | wsj.com

Exicure Warns of Need to Raise Additional Funds to Keep Operating

March 28, 2023 | finance.yahoo.com

Exicure, Inc. Reports Full Year 2022 Financial Results and Provides Corporate Update

March 20, 2023 | investing.com

Exicure (XCUR) Earnings Dates & Reports

January 15, 2023 | finance.yahoo.com

Exicure, Inc. (XCUR) Stock Historical Prices & Data - Yahoo Finance

November 15, 2022 | marketwatch.com

Exicure Warns of Needing Bankruptcy Protection if Deal with CBI USA Fails

November 15, 2022 | ca.finance.yahoo.com

Exicure, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update

September 28, 2022 | finance.yahoo.com

Exicure Lays Off Two-Third Employees, Ceases R&D Activities

September 27, 2022 | uk.investing.com

Jabil, TD Synnex And 3 Stocks To Watch Heading Into Tuesday By Benzinga - Investing.com UK

September 26, 2022 | benzinga.com

Exicure shares are trading higher after the company announced a workforce reduction and a private placeme - Benzinga

September 26, 2022 | investing.com

After-Hours Movers: Nautilus Gains on Strategic Review By Investing.com - Investing.com

September 26, 2022 | seekingalpha.com

Exicure to get $5.4M equity financing, reduce workforce & end R&D, preclinical activities - Seeking Alpha

September 26, 2022 | businesswire.com

Exicure, Inc. Enters Into Definitive Agreement With CBI USA, Inc. for $5.4 Million Equity Financing and Announces Implementation of Strategic Measure to Reduce Cash Burn and Prioritize Strategic Alternatives - Business Wire

See More Headlines

Receive XCUR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Exicure and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/19/2021
Today: 12/03/2023
Next Earnings (Estimated): 12/04/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:XCUR
CUSIP: N/A
CIK: 1698530
Web: www.exicuretx.com
Phone: (847) 673-1700
Fax: N/A
Employees: 7
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): $1.68
Trailing P/E Ratio: 0.28
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-2,580,000.00
Net Margins: N/A
Pretax Margin: 13.76%
Return on Equity: 34.49%
Return on Assets: 13.07%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.56
Quick Ratio: 2.56

Sales & Book Value

Annual Sales: $28.83 million
Price / Sales: 0.14
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.00 per share
Price / Book: 0.16

Miscellaneous

Outstanding Shares: 8,650,000
Free Float: 8,311,000
Market Cap: $4.07 million
Optionable: Not Optionable
Beta: 1.18

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. Paul Kang (Age 61)
CEO & Director
Ms. Jiyoung Hwang (Age 46)
CFO & Director
Mr. Joshua Miller (Age 47)
Chief Accounting Officer
Mr. Bart Anderson
Senior Director of R&D

Key Competitors

View All Competitors

Insiders

Cbi Usa, Inc.
Bought 3,400,000 shares on 12/15/2022
Total: $5.44 M ($1.60/share)

View All Insider Transactions

XCUR Stock Analysis - Frequently Asked Questions

How have XCUR shares performed in 2023?: Exicure's stock was trading at $1.15 on January 1st, 2023. Since then, XCUR shares have decreased by 59.1% and is now trading at $0.4701.
View the best growth stocks for 2023 here.
When is Exicure's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, December 4th 2023.
View our XCUR earnings forecast.
How were Exicure's earnings last quarter?: Exicure, Inc. (NASDAQ:XCUR) posted its quarterly earnings results on Friday, November, 19th. The company reported ($8.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.70) by $5.40. The business had revenue of ($3.68) million for the quarter, compared to analyst estimates of $0.80 million.

When did Exicure's stock split?: Exicure's stock reverse split on the morning of Thursday, June 30th 2022. The 1-30 reverse split was announced on Thursday, June 30th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 30th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.
How do I buy shares of Exicure?: Shares of XCUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:XCUR) was last updated on 12/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial